Is lercanidipine superior to ACE inhibitors or angiotensin‑II receptor blockers for managing hypertension in patients with renal dysfunction?

No, lercanidipine is not superior to ACE inhibitors or ARBs for managing hypertension in patients with renal dysfunction.

ACE inhibitors and ARBs remain the first-line antihypertensive agents for patients with chronic kidney disease (CKD), particularly those with albuminuria, due to their proven renoprotective effects that extend beyond blood pressure control. 1, 2, 3, 4

Evidence Hierarchy for Renal Protection

First-Line: RAAS Inhibitors (ACE-I/ARB)

The guideline evidence is unequivocal:

• For CKD with severely increased albuminuria (A3): ACE inhibitors or ARBs are strongly recommended (Grade 1B) for both diabetic and non-diabetic kidney disease 3, 4
• For CKD with moderately increased albuminuria (A2): ACE inhibitors or ARBs are recommended, though with weaker evidence in non-diabetic disease (Grade 2C for non-diabetic, Grade 1B for diabetic) 3, 4

These agents demonstrate:

• Reduction in progression to end-stage renal disease (ESRD)
• Decreased proteinuria independent of blood pressure lowering
• Prevention of "renal death" (death, dialysis, or transplantation) 1
• Slowed decline in GFR in both diabetic and non-diabetic CKD 5, 2

Second-Line: Calcium Channel Blockers (Including Lercanidipine)

Calcium channel blockers, including lercanidipine, are appropriate as second-line agents when:

• Blood pressure targets are not achieved with RAAS inhibitors alone
• RAAS inhibitors are contraindicated or not tolerated
• Additional blood pressure control is needed 6, 7

The 2025 ADPKD guideline specifically notes that while CCBs are "effective and safe," they show "less favorable impact on eGFR slope and albuminuria compared with RAAS inhibitors" 6.

Lercanidipine-Specific Evidence

While lercanidipine has some interesting properties, the evidence is limited:

Positive attributes:

• High lipophilicity providing sustained blood pressure control 8, 9
• Dilates both afferent and efferent glomerular arteries, theoretically preserving intraglomerular pressure 9
• One small study (ZAFRA, n=175) showed improved creatinine clearance when added to ACE-I/ARB therapy in CKD patients 10
• Reduced microalbuminuria in some studies 9

Critical limitations:

• No large randomized controlled trials demonstrating hard renal outcomes (ESRD prevention, mortality reduction)
• No head-to-head trials comparing lercanidipine directly to ACE-I/ARB for renal protection 11
• Evidence base consists primarily of small observational studies and surrogate endpoints
• The ZAFRA study only evaluated lercanidipine as add-on therapy to existing RAAS blockade, not as monotherapy 10

Clinical Algorithm for Hypertension in Renal Dysfunction

Step 1: Assess albuminuria and eGFR

• If UACR ≥300 mg/g (A3) with eGFR <60: Start ACE-I or ARB (mandatory) 3, 4
• If UACR 30-299 mg/g (A2) with eGFR <60: Start ACE-I or ARB (strongly preferred) 3, 4

Step 2: Target blood pressure <120/80 mmHg (when tolerated) 3, 4

Step 3: If BP not controlled on maximally tolerated RAAS inhibitor:

• Add thiazide-like diuretic (if eGFR >30) OR
• Add dihydropyridine CCB (lercanidipine is reasonable choice here) 6, 7

Step 4: Avoid:

• Combining ACE-I + ARB (increased adverse events without benefit) 2, 4
• Direct renin inhibitors in combination with ACE-I or ARB 4

Important Caveats

Monitor after initiating RAAS inhibitors:

• Check creatinine and potassium within 2-4 weeks 4
• Accept up to 30% rise in creatinine (hemodynamic effect, not harm) 4
• Discontinue only if creatinine rises >30% or uncontrolled hyperkalemia despite management 4

Lercanidipine advantages over other CCBs:

• Lower incidence of peripheral edema compared to amlodipine/nifedipine 8, 9
• May be preferred CCB choice if edema is problematic
• Well-tolerated in elderly and diabetic patients 8, 9

The bottom line: Lercanidipine is an effective and well-tolerated antihypertensive with potential renoprotective properties, but it should be used as adjunctive therapy to—not instead of—ACE inhibitors or ARBs in patients with renal dysfunction. The evidence supporting RAAS inhibition for preventing CKD progression and reducing mortality is robust and guideline-mandated, while lercanidipine's renal benefits remain largely theoretical or demonstrated only in small studies with surrogate endpoints.